Clinical Trial Update: Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis [Phase 2]

View source ↗

Summary

This Phase 2 trial compares bevacizumab against cidofovir for treating recurrent respiratory papillomatosis; current status is not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cidofovir (cidofovir)

Snippet

Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico | Conditions: Recurrent Respiratory Papillomatosis | Phase 2 | Status: UNKNOWN